SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Eustathios Kenanidis, Michael E Potoupnis, Panagiotis Kakoulidis, Andreas Leonidou, Grigorios T Sakellariou, Fares E Sayegh, Eleftherios Tsiridis, Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk, Expert Opinion on Drug Safety, 2015, 14, 7, 1035

    CrossRef

  2. 2
    Paul D. Miller, Management of severe osteoporosis, Expert Opinion on Pharmacotherapy, 2015, 1

    CrossRef

  3. 3
    Weiwei Dai, Li Jiang, Yu-An Evan Lay, Haiyan Chen, Guoqin Jin, Hongliang Zhang, Alexander Kot, Robert O. Ritchie, Nancy E. Lane, Wei Yao, Prevention of glucocorticoid induced bone changes with beta-ecdysone, Bone, 2015, 74, 48

    CrossRef

  4. 4
    Chi Chiu Mok, Ling Yin Ho, Kwok Man Ma, Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial, Bone, 2015, 75, 222

    CrossRef

  5. 5
    Roni P. Dodiuk-Gad, Sophia Ish-Shalom, Neil H. Shear, Systemic glucocorticoids: important issues and practical guidelines for the dermatologist, International Journal of Dermatology, 2015, 54, 6
  6. 6
    Cuoghi Edens, Angela Byun Robinson, Systemic lupus erythematosus, bone health, and osteoporosis, Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 6, 422

    CrossRef

  7. 7
    Yan Jiang, Yong Fu, Xiao-ping Xing, Mei Li, Ou Wang, Wei-bo Xia, Xun-wu Meng, Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis, European Journal of Medical Research, 2015, 20, 1

    CrossRef

  8. 8
    Robert A. Adler, Andrea Giustina, The Parathyroids, 2015,

    CrossRef

  9. 9
    Bo Abrahamsen, Dorthe Brask-Lindemann, Katrine Hass Rubin, Peter Schwarz, A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures, BoneKEy Reports, 2014, 3, 574

    CrossRef

  10. 10
    Natalia O Kuchuk, Jos N Hoes, Johannes WJ Bijlsma, Johannes WG Jacobs, Glucocorticoid-induced osteoporosis: an overview, International Journal of Clinical Rheumatology, 2014, 9, 3, 311

    CrossRef

  11. 11
    Holger Henneicke, Sylvia J. Gasparini, Tara C. Brennan-Speranza, Hong Zhou, Markus J. Seibel, Glucocorticoids and bone: local effects and systemic implications, Trends in Endocrinology & Metabolism, 2014, 25, 4, 197

    CrossRef

  12. 12
    E. Jódar Gimeno, Osteoporosis secundarias, Medicine - Programa de Formación Médica Continuada Acreditado, 2014, 11, 60, 3535

    CrossRef

  13. 13
    Salvatore Minisola, Romosozumab: from basic to clinical aspects, Expert Opinion on Biological Therapy, 2014, 14, 9, 1225

    CrossRef

  14. 14
    A. Scillitani, G. Mazziotti, C. Di Somma, S. Moretti, A. Stigliano, R. Pivonello, A. Giustina, A. Colao, Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?, Osteoporosis International, 2014, 25, 2, 441

    CrossRef

  15. 15
    Robert A. Overman, Joshua C. Toliver, Jun-Yen Yeh, Margaret L. Gourlay, Chad L. Deal, United States Adults Meeting 2010 American College of Rheumatology Criteria for Treatment and Prevention of Glucocorticoid-Induced Osteoporosis, Arthritis Care & Research, 2014, 66, 11
  16. 16
    D. Aeberli, Reference Module in Biomedical Sciences, 2014,

    CrossRef

  17. 17
    Eric Lespessailles, Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability, Joint Bone Spine, 2013, 80, 3, 258

    CrossRef

  18. 18
    Paola Villa, Maria C. Moruzzi, Anna P. Lassandro, Fulvio Leoni, Francesco Di Nardo, Chiara De Waure, Giovanni Scambia, Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population, Gynecological Endocrinology, 2013, 29, 7, 678

    CrossRef

  19. 19
    Bjoern Buehring, Ravi Viswanathan, Neil Binkley, William Busse, Glucocorticoid-induced osteoporosis: An update on effects and management, Journal of Allergy and Clinical Immunology, 2013, 132, 5, 1019

    CrossRef

  20. 20
    Amy H. Warriner, Kenneth G. Saag, Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids, Current Opinion in Endocrinology & Diabetes and Obesity, 2013, 20, 6, 510

    CrossRef

  21. 21
    Éric Lespessailles, Les bisphosphonates dans l’ostéoporose cortico-induite : efficacité et tolérance, Revue du Rhumatisme, 2013, 80, 2, 123

    CrossRef

  22. 22
    Sakura Yamamoto, Atsushi Suzuki, Hitomi Sasaki, Sahoko Sekiguchi-Ueda, Shogo Asano, Megumi Shibata, Nobuki Hayakawa, Shuji Hashimoto, Kiyotaka Hoshinaga, Mitsuyasu Itoh, Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease, Journal of Bone and Mineral Metabolism, 2013, 31, 1, 116

    CrossRef

  23. 23
    E. Michael Lewiecki, Robert A. Adler, John P. Bilezikian, Mary L. Bouxsein, Robert Marcus, Michael R. McClung, Paul D. Miller, S. Bobo Tanner, Susan Randall, Osteoporosis Update From the 2012 Santa Fe Bone Symposium, Journal of Clinical Densitometry, 2013, 16, 4, 584

    CrossRef

  24. 24
    Susan Hudec, Pauline Camacho, Secondary Causes of Osteoporosis, Endocrine Practice, 2013, 19, 1, 120

    CrossRef

  25. 25
    Robert A. Adler, Robert S. Weinstein, Kenneth G. Saag, Osteoporosis, 2013,

    CrossRef

  26. 26
    Michael T. McDermott, Endocrine Secrets, 2013,

    CrossRef

  27. 27
    Robert S. Weinstein, Glucocorticoid-Induced Osteoporosis and Osteonecrosis, Endocrinology and Metabolism Clinics of North America, 2012, 41, 3, 595

    CrossRef